1-4 of 4
Hui K. Gan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma

Available to Purchase
Lakshmi Nayak, Nathan Standifer, Jorg Dietrich, Jennifer L. Clarke, Gavin P. Dunn, Michael Lim, Timothy Cloughesy, Hui K. Gan, Elizabeth Flagg, Elizabeth George, Sarah Gaffey, Julia Hayden, Christina Holcroft, Patrick Y. Wen, Mary Macri, Andrew J. Park, Toni Ricciardi, Aileen Ryan, Paul Schwarzenberger, Ralph Venhaus, Melissa de los Reyes, Nicholas M. Durham, Todd Creasy, Raymond Y. Huang, Thomas Kaley, David A. Reardon
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2567–2578.
https://doi.org/10.1158/1078-0432.CCR-21-4064
Published: 13 June 2022
View articletitled, Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
Open the PDF for Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity

Available to Purchase
Hui K. Gan, Michael Millward, Ye Hua, Chuan Qi, Yang Sai, Weiguo Su, Jian Wang, Lilin Zhang, Melanie M. Frigault, Shethah Morgan, Liu Yang, Jason D. Lickliter
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 4924–4932.
https://doi.org/10.1158/1078-0432.CCR-18-1189
Published: 15 August 2019
View articletitled, First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity
Open the PDF for First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma

Free
Andrew B. Lassman, Lisa Roberts-Rapp, Irina Sokolova, Minghao Song, Ekaterina Pestova, Rupinder Kular, Carolyn Mullen, Zheng Zha, Xin Lu, Erica Gomez, Anahita Bhathena, David Maag, Priya Kumthekar, Hui K. Gan, Andrew M. Scott, Maria Guseva, Kyle D. Holen, Peter J. Ansell, Martin J. van den Bent
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (11): 3259–3265.
https://doi.org/10.1158/1078-0432.CCR-18-3034
Published: 03 June 2019
View articletitled, Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma
Open the PDF for Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor–Specific Antibody Generates Enhanced Antitumor Activity

Available to Purchase
Rushika M. Perera, Yoshitaka Narita, Frank B. Furnari, Hui K. Gan, Carmel Murone, Marika Ahlkvist, Rodney B. Luwor, Antony W. Burgess, Elisabeth Stockert, Achim A. Jungbluth, Lloyd J. Old, Webster K. Cavenee, Andrew M. Scott, Terrance G. Johns
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (17): 6390–6399.
https://doi.org/10.1158/1078-0432.CCR-04-2653
Published: 06 September 2005
View articletitled, Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor–Specific Antibody Generates Enhanced Antitumor Activity
Open the PDF for Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor–Specific Antibody Generates Enhanced Antitumor Activity in another window